EssilorLuxottica and CooperCompanies Announce Joint Venture for Acquisition of SightGlass Vision and Move to Expand Myopia Management Category

By
CHARENTON-LE-PONT, France, and SAN RAMON, Calif.—EssilorLuxottica (Reuters: ESLA.PA) and CooperCompanies (NYSE:COO), two of the world’s leading vision care companies, said late Wednesday that they have entered into an agreement to create a 50/50 joint venture for the acquisition of SightGlass Vision, a U.S.-based life sciences company focused on developing innovative spectacle lenses to reduce the progression of myopia in children. EssilorLuxottica and CooperCompanies will leverage their shared expertise and global leadership in myopia management to accelerate the commercialization of SightGlass Vision spectacle lenses.

Through this partnership, they will further strengthen innovation opportunities and go-to-market capabilities to grow the myopia control category, the announcement noted.

SightGlass Vision’s technology will complement both companies’ existing solutions, including Essilor’s Stellest lens and CooperVision’s MiSight and Orthokeratology contact lenses. (VMAIL reported on the recent success of the Stellest lens in slowing myopia progression here.)

The joint venture will acquire SightGlass Vision from CooperCompanies, and the closing of the acquisition and creation of the joint venture is subject to regulatory approvals and other customary closing conditions. CooperCompanies previously held a minority ownership interest in SightGlass Vision and completed its acquisition of SightGlass Vision in January 2021, the announcement noted.

The financial terms of the transaction were not disclosed.



In a separate announcement, CooperVision also noted that the new JV agreement will help to accelerate commercialization of the innovative spectacle lenses from SightGlass Vision that are designed to reduce the progression of myopia in children. CooperVision said it has been at “the forefront of creating the global myopia management category to help millions of children and their caregivers,” and the support of “evidence-based spectacle options will help accelerate category growth, especially among younger patients.”

“We are excited to join forces with CooperCompanies, a company with a strong track record in addressing major vision conditions, including myopia, and leverage together the SightGlass Vision technology,” Francesco Milleri and Paul du Saillant, CEO and deputy CEO, respectively, of EssilorLuxottica, said in the announcement.

“This partnership is fully consistent with EssilorLuxottica’s strategy to improve access to vision care, including solutions that can control myopia progression. The complementarity of our existing solutions, including Essilor’s recent Stellest lens, with SightGlass Vision’s promising technology will further strengthen our offer by providing advanced products answering to the growing needs of customers and consumers worldwide.”

Al White, president and CEO of CooperCompanies, said, “EssilorLuxottica is a pioneer and global leader in the vision space and expanding our relationship to better tackle the rapidly growing myopia management marketplace is extremely exciting. By combining our strengths, we look forward to increasing the life-changing offerings available to global eyecare practitioners to combat childhood myopia. This partnership is a natural extension to our existing portfolio of innovative myopia management products, including MiSight contact lenses, and we firmly believe this partnership will strengthen our ability to accelerate those offerings.”

Added Daniel McBride, president of CooperVision, “Our collaboration with Essilor delivers on our promise to make myopia management accessible and the standard of care for treating childhood myopia. With the SightGlass Vision technology from this collaboration, MiSight 1 day and orthokeratology contact lenses from CooperVision, and Stellest lenses from Essilor, ECPs can create a comprehensive optical intervention portfolio to treat the growing number of children impacted by myopia. Eyecare professionals and caregivers need access to a range of effective treatments, and we are committed to bringing effective products to market for them.”

The last few decades have seen a steady rise in the prevalence of myopia across the globe, notably under the effect of lifestyle changes. Today affecting 2.6 billion people worldwide, it is estimated that nearly 5 billion people, or half of the world population, will be myopic by 2050.

Myopia is the leading cause of visual impairment in children and, over time, may contribute to an increased risk of developing permanent vision impairment, including macular degeneration, retinal detachment, cataract and glaucoma, and blindness associated with high myopia.

By combining their scientific expertise and product development capabilities, EssilorLuxottica and CooperCompanies intend to increase awareness and offer additional solutions to help address this global eye health issue.